Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-12-18

Clinical Trial Update: Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy of vortioxetine for generalized anxiety disorder; results were posted in December 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vortioxetine (vortioxetine)

Snippet

Sponsor: Takeda | Conditions: Generalized Anxiety Disorder | Phase 3 | Status: COMPLETED | Results posted: 2013-12-18